Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

Targeted oncology - 1 Jun 2017

Serrano César, George Suzanne, Valverde Claudia, Olivares David, García-Valverde Alfonso, Suárez Cristina, Morales-Barrera Rafael, Carles Joan

Abstract excerpt

Gastrointestinal stromal tumors (GIST) have emerged as a compelling clinical and biological model for the rational development of therapeutic strategies targeting critical oncogenic events over the past two decades. Oncogenic activation of KIT or PDGFRA receptor tyrosine kinases is the crucial driver for GIST tumor initiation, transformation, and cancer cell proliferation. Three tyrosine kinase inhibitors (TKIs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Neoplasms

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Source

Identifiers

PMID: 28478525
DOI: 10.1007/s11523-017-0490-9

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.PMID 28478525Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Translational insights into gastrointestinal stromal tumor and current clinical advances.Semantic proximity Read ↗

Gastrointestinal stromal tumors.Semantic proximity Read ↗

Gastrointestinal stromal tumors (GISTs): from science to targeted therapy.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.Semantic proximity Read ↗

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Semantic proximity Read ↗

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.